immunotherapy

Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO…

1 year ago

HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

— HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative…

1 year ago

Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV

Current Renovaro Chairman to Lead Subsidiary’s Development Program and Commercialization LOS ANGELES and AMSTERDAM, Dec. 30, 2024 (GLOBE NEWSWIRE) --…

1 year ago

Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies

Coeptis Aims to Bring AI Innovation in Biotechnology and Technology WEXFORD, Pa., Dec. 26, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings,…

1 year ago

RenovaroCube Receives Approval of Lumina Project by the Eurostars Funding Program

LUMINA is an Advanced Minimal Residual Disease Detection Platform for Lung Cancer Harnessing the Power of Multi-omics Biomarkers and AI…

1 year ago

Art Bio Miami and The Global Passion Projects: Where Scientific Innovation, Creativity and Philanthropy Converge to Transform Lives

Miami, Florida--(Newsfile Corp. - December 21, 2024) - Amid the vibrant backdrop of Art Basel week, Art Bio Miami and…

1 year ago

Driving Innovation in Epigenetics: EpiCypher’s 2024 Impact in Chromatin Research

DURHAM, N.C., Dec. 20, 2024 /PRNewswire/ -- EpiCypher proudly celebrates a landmark year in 2024, with seven peer-reviewed publications and…

1 year ago

Renovaro Enters into a Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection

Renovaro will Establish the GEDi CUBE Next Generation Nvidia Blackwell Cluster with Nebul's certified AI Healthcare Cloud solutions LOS ANGELES,…

1 year ago

Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH

In the pre-specified per-protocol population, belapectin showed a statistically significant reduction (p-value < 0.05) in development of esophageal varices in…

1 year ago